If you’ve heard about Zepbound® (tirzepatide) and are wondering whether Medicare will help pay for it in 2026, you’re not alone. Millions of older Americans struggle with obesity and its complications, including heart disease, sleep apnea, arthritis, high...
If you’ve heard about Medicare’s new GLP-1 Bridge Program, you may be wondering: “Will Medicare pay for Wegovy® in 2026?” The short answer is yes—but it depends on why you’re taking Wegovy and whether you meet the program’s...
Over the past several years, GLP-1 medications have transformed the treatment of obesity and Type 2 diabetes. While many people recognize these medications for their ability to promote significant weight loss, researchers have discovered that their benefits extend far...